Filed Pursuant to Rule 424(b)(5)
Registration Statement No. 333-266672
SUBJECT TO COMPLETION
PRELIMINARY PROSPECTUS SUPPLEMENT DATED NOVEMBER 18, 2024.
PRELIMINARY PROSPECTUS SUPPLEMENT
(To Prospectus dated August 17, 2022)
DEPOSITARY SHARES
Each Representing a 1/40th Interest in a Share of
% Fixed Rate
Series E Non-Cumulative Perpetual Preferred Stock
We are offering depositary shares each representing a 1/40th ownership interest in a share of our % Fixed Rate Series E Non-Cumulative Perpetual Preferred Stock, without par value (“Series E preferred stock”), with a liquidation preference of $1,000 per share of Series E preferred stock (equivalent to $25 per depositary share). As a holder of depositary shares, you will be entitled to all rights and preferences of the Series E preferred stock (including dividend, voting, redemption and liquidation rights) in proportion to your investment in the underlying shares of Series E preferred stock. You must exercise these rights through the depositary.
Dividends on the Series E preferred stock will not be cumulative or mandatory. If our board of directors does not declare a dividend on the Series E preferred stock or if our board of directors authorizes and we declare less than a full dividend in respect of any Dividend Period (as defined herein), we will have no obligation to pay a dividend or to pay full dividends for that Dividend Period at any time, whether or not dividends on the Series E preferred stock or any other class or series of our preferred stock or common stock are declared for any future Dividend Period.
We will pay dividends on the Series E preferred stock, when, as, and if declared by our board of directors. Dividends will be payable from the original date of issuance at a rate of % per annum, payable quarterly in arrears, on January 1, April 1, July 1 and October 1 of each year, beginning on January 1, 2025. Upon payment of any dividend on the Series E preferred stock, holders of depositary shares are expected to receive such dividends in proportion to their investment in the depositary shares representing such Series E preferred stock.
We may redeem the Series E preferred stock at our option, subject to regulatory approval, at a redemption price equal to $1,000 per share (equivalent to $25 per depositary share), plus any declared and unpaid dividends (without regard to any undeclared dividends) to, but excluding, the redemption date, (i) in whole or in part, from time to time, on any Dividend Payment Date (as defined herein) on or after January 1, 2030 or (ii) in whole, but not in part, at any time within 90 days following a Regulatory Capital Treatment Event (as defined herein). If we redeem the Series E preferred stock, the depository shall redeem a proportionate number of depositary shares.
The Series E preferred stock will rank (i) senior to our common stock, (ii) equally with our 8% Non-Cumulative, Perpetual Preferred Stock, without par value, liquidation preference $1,000 per share (the “8% Preferred”), our 7.00% Fixed-to Floating Rate Series A Non-Cumulative Perpetual Preferred Stock, without par value, liquidation preference of $25 per share (the “Series A preferred stock”), our 6.00% Fixed-to-Floating Rate Series B Non-Cumulative Perpetual Preferred Stock, without par value, liquidation preference of $1,000 per share (equivalent to $25 per depositary share) (the “Series B preferred stock”), our 6.00% Fixed Rate Series C Non-Cumulative Perpetual Preferred Stock, without par value, liquidation preference of $1,000 per share (equivalent to $25 per depositary share) (the “Series C preferred stock”), our 8.25% Fixed Rate Reset Series D Non-Cumulative Perpetual Preferred Stock (the “Series D preferred stock,” and together with the 8% Preferred, the Series A preferred stock, the Series B preferred stock, the Series C preferred stock, and the Series E preferred stock, “Preferred Stock”), and (iii) at least equally with each other series of our preferred stock we may issue (except for any senior series that may be issued with the requisite consent of the holders of the Preferred Stock and all other parity stock), with respect to the payment of dividends and rights (including redemption payments) upon liquidation, dissolution or winding up.
Currently no market exists for the depositary shares. We have filed an application to list the depositary shares on the Nasdaq Capital Market (“Nasdaq”) under the symbol “MBINL”. If the application is approved, trading of the depositary shares on Nasdaq is expected to begin within 30 days after the date of initial issuance of the depositary shares.
At our request, Morgan Stanley & Co. LLC has reserved out of the depositary shares being offered by this prospectus depositary shares for sale at the public offering price to eligible employees, officers, directors and persons having a relationship with us through a directed share program.
|
|
|
Per Depositary Share
|
|
|
Total
|
|
Public offering price
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
|
Underwriting discounts and commissions(1)
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
|
Proceeds to us, before expenses
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
|
(1)
The underwriting discount of $ per share will be deducted from the public offering price; provided, however, that for sales through the directed share program, the underwriting discount will be $ per share, and to institutions, the underwriting discount will be $ per depositary share. The underwriters will also be reimbursed for certain expenses incurred in this offering. See “Underwriting.”
We have granted the underwriters an option to purchase up to an additional depositary shares within 30 days after the date of this prospectus supplement at the public offering price, less underwriting discounts and commissions, solely to cover over-allotments, if any.
The underwriters expect to deliver the depositary shares in book-entry form only, through the facilities of The Depository Trust Company (“DTC”) for the accounts of its participants against payment therefor on or about , 2024, which is the fifth business day following the date of pricing of the depositary shares (such settlement being referred to as “T+5”). See “Underwriting” for details.
None of the Securities and Exchange Commission (the “SEC”), any state securities commission, the Federal Deposit Insurance Corporation (the “FDIC”), the Board of Governors of the Federal Reserve System (the “Federal Reserve”) or any other regulatory body has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Neither the depositary shares nor the Series E preferred stock is a savings account, deposit or other obligation of any of our bank or non-bank subsidiaries and neither is insured by the FDIC or any other governmental agency or instrumentality.
Joint-Lead Bookrunning Managers
|
Morgan Stanley
|
|
|
UBS Investment Bank
|
|
|
Piper Sandler
|
|
|
Raymond James
|
|
The date of this prospectus supplement is , 2024.